Literature DB >> 23380250

Control trial and fecal egg count reduction test determinations of nematocidal efficacies of moxidectin and generic ivermectin in recently weaned, naturally infected calves.

T A Yazwinski1, C A Tucker, E Wray, L Jones, J Reynolds, P Hornsby, J Powell.   

Abstract

An anthelmintic efficacy study was performed with young, naturally infected beef-type calves obtained at local farms. Presumably, the study calves had been recently weaned and had not been treated with a parasiticide prior to study acquisition. After blocking the 24 study calves in accordance with calculated Cooperia spp EPG counts, the calves were randomly allocated within each block to one of four treatment groups, resulting in 6 animals per treatment group (untreated controls, topical ivermectin at the rate of 500 mcg/kg BW [Noromectin Pour-On(®) Norbrook], topical moxidectin at the rate of 500 mcg/kg BW [Cydectin Pour-On(®) Boehringer Ingelheim Vetmedica (BIVM)] and injectable moxidectin at the rate of 200 mcg/kg BW [Cydectin(®) BIVM]. After treatment, the animals were penned by treatment group until necropsy. Fecal, strongyle egg count reduction percentages at 2 days post-treatment were 13, 52, 81 and 93 for control, topical ivermectin, topical moxidectin and injectable moxidectin treatment groups, respectively. In the same order as above, egg count reduction percentages at necropsy (15-18 days post-treatment) were -14, 91, 94 and 97. Based on geometric means for worm burdens quantified at necropsy, anthelmintic efficacies ranged from 96 to 100% for adult Oesophagostomum radiatum, Ostertagia ostertagi, Haemonchus placei and Trichostrongylus axei. Against adult Nematodirus helvetianus, percent efficacies based on geometric means were 56.7, 98.3 and 82.2 for topical ivermectin, topical moxidectin and injectable moxidectin, respectively; an observation that is guarded, as only 5 control animals were infected with adult N. helvetianus. Respective anthelmintic efficacies (%'s) against adult Cooperia oncophora and C. punctata were 93.0 and 73.4 (topical ivermectin), 99.3 and 99.9 (topical moxidectin) and 46.1 and 93.6 (injectable moxidectin). Judging from these data, it appears that treatment of calves soon after weaning with topical moxidectin is effective (>90% efficacy) for all common nematodes in cattle, but injectable moxidectin and topical ivermectin have limited effectiveness against Cooperia spp. With Cooperia spp and H. placei infections, the fecal egg count reduction test and the control trial determinations of anthelmintic effectiveness were in disagreement regarding injectable moxidectin and topical ivermectin.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380250     DOI: 10.1016/j.vetpar.2012.12.061

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  3 in total

1.  Modelling the consequences of targeted selective treatment strategies on performance and emergence of anthelmintic resistance amongst grazing calves.

Authors:  Zoe Berk; Yan C S M Laurenson; Andrew B Forbes; Ilias Kyriazakis
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-11-16       Impact factor: 4.077

2.  Gastrointestinal Nematodes of Goats: Host-parasite Relationship Differences in Breeds at Summer Mountain Pasture in Northern Italy.

Authors:  Sergio Aurelio Zanzani; Alessia Libera Gazzonis; Emanuela Olivieri; Luca Villa; Cristina Fraquelli; Maria Teresa Manfredi
Journal:  J Vet Res       Date:  2019-12-19       Impact factor: 1.744

Review 3.  Emerging Anthelmintic Resistance in Poultry: Can Ethnopharmacological Approaches Offer a Solution?

Authors:  Gerald Zirintunda; Savino Biryomumaisho; Keneth Iceland Kasozi; Gaber El-Saber Batiha; John Kateregga; Patrick Vudriko; Sarah Nalule; Deogracious Olila; Mariam Kajoba; Kevin Matama; Mercy Rukundo Kwizera; Mohammed M Ghoneim; Mahmoud Abdelhamid; Sameh S Zaghlool; Sultan Alshehri; Mohamed A Abdelgawad; James Acai-Okwee
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.